Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Sep / Animal Alternatives
Manufacture Quality & Compliance

Animal Alternatives

Developing in vitro methods that help vaccine developers reduce animal testing

By Maryam Mahdi 09/14/2020 1 min read Quick Read (pre 2022)

Share

Though animal testing is an essential part of vaccine R&D, Gideon Kersten, Chief Scientific Officer at Intravacc, believes its role in quality control is debatable. “Not only have our analytical capabilities improved spectacularly, but production processes are now better controlled,” he says. “It should be possible to reduce our animal use if in vitro tests can prove a vaccine is produced in a consistent manner.”

Intravacc, in collaboration with researchers from Leiden University, the Netherlands, has developed a technique that relies on the enzyme cathepsin S to establish the quality of vaccines (1). Cathepsin S can be used to measure how consistent purified native pathogens in vaccines are inactivated. “The inactivation step in the development of some vaccine types is critical and relies often on formaldehyde,” says Kersten. “Using mass spectrometry, we quantified how quickly the enzyme breaks down proteins in vaccine products. The rate of degradation was used as an indicator of how well formaldehyde inactivated the vaccines we tested.”

Though the process initially seemed straightforward, the team soon realized that it would be difficult to execute. “Using formaldehyde is really messy! The protein fragments we studied were not only inactivated, but extensively modified by the compound, and we ended up with a heterogeneous mixture,” Kersten says. “Though we mapped these modifications in great detail, we then turned our focus to quantifying the breakdown of peptides that were not modifiable because identification of unmodified peptides by mass spectrometry is easier.”

The change in direction allowed the team to accurately determine the effect of cathepsin S on degradation. “We now have a method that allows us to establish vaccine quality without animal testing,” Kersten says. 

The team is now working towards validating their approach before seeking regulatory approval.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. TJM Michiels et al., Sci Rep, 10, 11535 (2020).

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Innovating Pharmaceutical Packaging
Quality & Compliance Supply Chain
Innovating Pharmaceutical Packaging

March 25, 2025

3 min read

Michiel van den Berg sheds light on the challenges and opportunities facing the industry as it adapts to new materials and regulatory requirements, offering expert insights into the future of pharmaceutical packaging.

AI Approach to Transdermal GLP-1s
Advanced Medicine Bioprocessing - Single Use Systems Bioprocessing - Upstream & Downstream Dosage Forms Contract Manufacturing Services Biosimilars Packaging Process Control Supply Chain Quality & Compliance
AI Approach to Transdermal GLP-1s

February 25, 2025

3 min read

How do you design, refine, and optimize novel GLP-1 drugs that could improve patient experiences? With a computer, of course.

Using the Right Excipients to Mitigate Nitrosamine Formation
Formulation Quality & Compliance Small Molecules
Using the Right Excipients to Mitigate Nitrosamine Formation

January 21, 2025

3 min read

In 2018, nitrosamines were discovered in some pharmaceuticals. The industry has since been under pressure to reduce the risks in both in-development and on-market drug products.

Ambition, Innovation, Impact: The Future of Cleanroom Standards
Process Control Quality & Compliance Standards & Regulation
Ambition, Innovation, Impact: The Future of Cleanroom Standards

December 4, 2024

5 min read

The rocket-fueled dreams of a young engineer applied to the cleanroom industry. Sitting down with Kevin Kyle, CEO, Germfree, who shares insights on the dynamic landscape of cleanroom design and deployment.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.